linjc16/ctgov huggingface dataset:
TinCat LGBTQ+ Smoking Cessation Via Asynchronous Telehealth

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the efficacy of a novel telehealth-based intervention to reduce tobacco use among LGBTQ+ people.

Detailed Description
-----------------
After being informed about potential risks and screened into the study, patients will be randomized into the treatment or control group. Control group participants will complete 7 sessions based on quit.gov smoking cessation planning. Intervention participants will complete 7 sessions of individualized asynchronous telehealth sessions.

Official Title
-----------------
TinCat Tobacco Cessation Protocol for LGBTQ+ Austinites

Conditions
-----------------
Tobacco Use Disorder, Tobacco Use Cessation

Intervention / Treatment
-----------------
* Behavioral: TinCat
* Behavioral: Quit.gov program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 and over Live in Greater Austin Identify as LGBTQ+ Current smokers High speed internet access Exclusion Criteria: Exceed screener cutoff for suicide risk Exceed screener cutoff for borderline personality disorder Report current active substance use other than tobacco that interferes with functioning

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Participants will be assigned to the control or intervention groups randomly.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Quit.gov program<br>Generic intervention based on quit.gov sessions. | Behavioral: Quit.gov program<br>* 7-10 minute generic videos directing participants through quit.gov program<br>|
| Experimental: TinCat<br>Individualized asynchronous telehealth including LGBTQ+ affirming components. | Behavioral: TinCat<br>* 7-10 minute personalized video sessions based in tobacco cessation modules.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tobacco use | Cigarette and vape assessments based on prior research on vaping/smoking: Cigarette: Today, did you have at least one puff on a cigarette (yes/no) IF YES, THEN How many cigarettes did you smoked (at least one puff) (1-more than 60). Vaping: Today, did you use an electronic nicotine delivery system (i.e., a vape containing nicotine), even just one puff? (yes/no) IF YES, THEN How many times they had at least one puff (1 time, 2-5 times, 6-10 times, 11-15 times, 16-20 times, 21-25 times, 26-30 times, 31 or more times). | 11 weeks |
A Novel Motivational Ecological Momentary Intervention for Anorexia Nervosa

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to pilot an innovative motivational text-message intervention for individuals with anorexia nervosa and subthreshold anorexia nervosa. Patients will receive personalized motivational text-messages as an adjunct to cognitive behavioral therapy (CBT). CBT will be provided to patients at no cost for the duration of the study. The investigators hypothesize that the text-messages will help increase motivation to change and kilocalorie intake and decrease eating disordered behavior.

Conditions
-----------------
Eating Disorders

Intervention / Treatment
-----------------
* Behavioral: Text-Message Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Anorexia nervosa/subthreshold anorexia nervosa (i.e., individuals who exhibit significant dietary restraint) 18+ years old Exclusion Criteria: BMI < 16.5 Medication instability for 6 weeks Recent/current suicidal risk Comorbid substance abuse or dependence, bipolar disorder, schizophrenia, or mental retardation Inability to provide release of information to a medical provider

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Text-Message Intervention<br>Participants will undergo four weeks (in a randomized order) of receiving personalized motivational text-messages while receiving CBT for their eating disorder. | Behavioral: Text-Message Intervention<br> <br> |
| No Intervention: No Text Message Phase<br>Participants will receive 4 randomized weeks of not receiving text messages while receiving CBT for their eating disorder. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Motivation to Change Eating Disorder Behaviors |  | Daily for 8 weeks | 
| Change in Eating Disorder Symptoms |  | Daily for 8 weeks | 
| Kilocalorie Intake (measured by self-report food records) |  | Daily for 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility measured by compliance with daily questionnaire |  | 8 weeks | 
| Acceptability measured by self-report ratings |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
eating disorders, anorexia nervosa, treatment, technology
Genetic Investigations in Spontaneous Coronary Artery Dissection (SCAD)

Study Overview
=================
Brief Summary
-----------------
The purpose of the research is to identify mutations (defects in the genetic blueprint) that cause spontaneous coronary artery dissection (SCAD), in other words, spontaneous tears in blood vessels that supply the heart. Some mutations may be inherited (passed on) from a parent without an apparent blood vessel problem while others may develop for the first time in the affected person.

Detailed Description
-----------------
Study question: Do mutations within certain genes cause or confer susceptibility to spontaneous coronary artery dissection (SCAD)? Specific aims: Create a genomic DNA and plasma biobank for individuals diagnosed with SCAD. Identify inherited and de novo/new mutations that underlie SCAD. Identify common genetic variants that confer risk for SCAD. Long term objective:Discover molecular and cellular mechanisms of SCAD and develop biomarkers to enable prediction and prevention. The purpose of the research is to identify mutations (defects in the genetic blueprint) that cause tears in blood vessels that supply the heart. Some mutations may be inherited (passed on) from a parent without an apparent blood vessel problem while others may develop for the first time in the affected person. The study includes individuals diagnosed with spontaneous coronary artery dissection, their biological parents, and relatives with fibromuscular dysplasia, arterial aneurysm, or arterial dissection. Adults with SCAD will be identified both retrospectively and prospectively.Confirmation of the diagnosis by review of coronary angiography will be required before proceeding with the informed consent process and blood or saliva sample procurement.

Official Title
-----------------
Genetic Investigations in Spontaneous Coronary Artery Dissection (SCAD)

Conditions
-----------------
Spontaneous Coronary Artery Dissection, SCAD

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women able to give informed consent and complete a 2 page questionnaire Diagnosis of one or more episodes of spontaneous coronary artery dissection (SCAD) Biological parent of individual with SCAD Relative with fibromuscular dysplasia, arterial aneurysm, or arterial dissection Exclusion Criteria: Lack of confirmation of SCAD diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of one or more gene mutation responsible for SCAD | Via GWAS and whole exome sequencing | By end of study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SCAD, Spontaneous coronary artery dissection
Goal Achievement and Patient Satisfaction in Benign Hysterectomy

Study Overview
=================
Brief Summary
-----------------
This study evaluates patient goal achievement and satisfaction in benign hysterectomy. Patient's will state their goals prior to undergoing benign hysterectomy, and will receive a follow-up questionnaire 3 months post-operatively evaluating their perception of goal achievement and overall satisfaction. Goal achievement and satisfaction will be evaluated for association with surgical indication, surgical approach (minimally invasive vs abdominal surgery), and demographic information.

Official Title
-----------------
Goal Achievement and Patient Satisfaction in Benign Hysterectomy

Conditions
-----------------
Hysterectomy, Goal Achievement, Patient Satisfaction, Minimally Invasive Surgery

Intervention / Treatment
-----------------
* Other: Questionnaire 3 months post-operatively


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient undergoing hysterectomy for benign indication Age 18 or greater English speaking Access to communication via telephone Exclusion Criteria: Patient undergoing hysterectomy for malignant or pre-malignant condition Non-english speaking patient Patient without telephone access Patient undergoing emergent or unplanned hysterectomy Vulnerable populations

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Minimally invasive hysterectomy<br>Patients undergoing scheduled minimally invasive hysterectomy (vaginal, laparoscopic, robotic) for benign condition | Other: Questionnaire 3 months post-operatively<br> <br> |
| Abdominal hysterectomy<br>Patients undergoing scheduled abdominal hysterectomy for benign condition | Other: Questionnaire 3 months post-operatively<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Goal achievement score of 4 or 5 | Patients will state their goals prior to surgery, then at the three months post-operatively will rank if their goals were met on a 1-5 likert scale (1=strongly disagree, 2=disagree, 3=neutral, 4=agree, 5=strongly agree). Goals are considered achieved with a likert score of 4 or 5. | 3 months post-operatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent of patient satisfaction | At three months post-operatively, patients will state how satisfied they are with their hysterectomy experience, from 0 to 100%. | 3 months post-operatively |
Cohort of Patients Naive of Antiretroviral Treatment at Enrollment

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the short, medium and long-term prognosis for newly diagnosed HIV patients.

Detailed Description
-----------------
The purpose of this study is to evaluate the short, medium and long-term prognosis for newly diagnosed HIV patients. This study aims to precise the impact of HIV infection treatment on morbidity and mortality, the factors related to treatment response, clinical and biological complications, their consequences, especially lipodystrophy and metabolic abnormalities, associated factors especially genetic, aspects linked to aging. In addition, the study describes the evolution of patients living conditions and behaviors remotely from their screening, particularly related to sexuality, reproduction, and health inequalities and to study the long-term treatment adherence. One third of the patients were included in the metabolic disorders module. This module includes additional biological and imaging explorations.

Official Title
-----------------
Cohort of Patients Naive of Antiretroviral Treatment at Enrollment

Conditions
-----------------
HIV Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients infected with HIV-1, with a recent diagnosis (<1 year before enrollment) Untreated at the time of enrollment, Aged 15 or more Agreeing to participate in the cohort. Exclusion Criteria: Under protection(saving) of justice

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients prognosis at short, medium and long term |  | Up to 12 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antiretroviral treatment impact | therapeutical adherence, factors related with treatment response | Up to 12 years | 
| Aging population | Study of caracteristics of the population over 50 years old (quality of life or comorbidities... in questionnaire and autoquestionnaire) | up to 12 years | 
| Impact of inflammatory markers on antiretroviral treatment | from blood collection: IL-6, sTNF-R1, sTNF-R2, CD14, CRP | Up to 12 years | 
| Socio-economic conditions (sexuality, education, reproduction, health inequalities) | Completed in annual questionnaire and auto-quesitonnaire by the patient and the physician | Up to 12 years |
Reconstruction of Digital Nerve Lesions With Muscle-in-Vein Conduits

Study Overview
=================
Brief Summary
-----------------
Muscle-in-vein conduits (MVCs) provide an alternative for bridging digital nerve defects when tension-free suture is not possible. Low donor site morbidity and absence of additional costs are favorable advantages compared to autografts or conduits. 37 patients with 43 defects of proper palmar digital nerves were retrospectively enrolled. Primary repair by MVCs was performed in 22 cases while 21 underwent secondary reconstruction. Recovery of sensibility was assessed by static and moving two-point discrimination (2PDs, 2PDm) and Semmes-Weinstein monofilaments (SWM). Results were compared with contralateral side serving as intraindividual control. Outcome data were stratified according to international guidelines and evaluated for differences in terms of age, gap length, time of reconstruction and concomitant injuries.

Official Title
-----------------
Outcome After Reconstruction of 43 Digital Nerve Lesions With Muscle-in-Vein Conduits

Conditions
-----------------
Peripheral Nerve Injury Upper Limb

Intervention / Treatment
-----------------
* Other: Nerve reconstruction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients with reconstruction of digital nerves with muscle-in-vein conduits Exclusion Criteria: Subtotal or total amputations pre-existing neurological disorders (e.g. polyneuropathy) symptoms of nerve entrapment

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 72 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Digital nerve reconstruction with muscle-in-vein conduits<br> | Other: Nerve reconstruction<br>* Nerve bridging with muscle-in-vein conduits<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Two-point discrimination |  | Six months after reconstruction or later | 
| Semmes-Weinstein-Monofilament test |  | Six months after reconstruction or later | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Age |  | Baseline | 
| Gap length |  | Baseline | 
| Time of reconstruction |  | Baseline | 
| Concomitant injuries |  | Baseline |
Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study.

Study Overview
=================
Brief Summary
-----------------
Methotrexate (MTX) is considered the 'gold-standard' drug for the treatment of severe psoriasis. Health-related quality of life (HRQOL) is impaired in patients with psoriasis, more so if disease is severe.

Official Title
-----------------
Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study.

Conditions
-----------------
Severe Plaque Type Psoriasis

Intervention / Treatment
-----------------
* Drug: Methotrexate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age range 18 to 65 years Both sexes Severe plaque-type psoriasis (BSA >10% or PASI >12) - Exclusion Criteria: Pregnancy Lactation Malignancy or immunosuppression including HIV Liver disease Renal disease Non compliant Psychiatric illness Hypersensitivity to methotrexate in the past -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group A<br>Methotrexate 10mg orally once weekly | Drug: Methotrexate<br> <br> |
| Active Comparator: Group B<br>Methotrexate 25mg orally once weekly | Drug: Methotrexate<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in health related quality of life |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| comparison of improvement in health related quality of life between Group A and Group B |  | 12 weeks |
The Effects of Gastric Tube on the Quality of Life and Nutritional Status After Ivor-Lewis Esophagectomy

Study Overview
=================
Brief Summary
-----------------
This study is to investigate the effects of narrowed gastric tube on postoperative nutritional status and the quality of life in esophageal cancer patients treated with Ivor-Lewis esopagectomy in a 12-month follow-up period.

Official Title
-----------------
The Effects of Gastric Tube on the Quality of Life and Nutritional Status After Ivor-Lewis Esophagectomy: A Randomized Control Trial and Physiological Study

Conditions
-----------------
Oesophageal Cancer

Intervention / Treatment
-----------------
* Procedure: gastric tube


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: esophageal cancer (squamous and adenocarcinoma subtypes) eligble for Ivor-Lowis esophagectomy expected survival time longer than 12 months Exclusion Criteria: palliative resection(non-R0) anastomosis leak jejunum or colon transversum interponate

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: gastirc tube group<br>conduit will be perfomed by narrowed gastric tube | Procedure: gastric tube<br>* the stomach will be cut into a narrowed tube-shape conduit<br>|
| No Intervention: control group<br>conduit will be traditional subtotal stomach without any surgical modification | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change of nutritional status and quality of life before and after operation |  | before operation (baseline), 1 month, 6 month and 12 month after operation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change of serum markers and tissue inflammatory status before and after operation |  | before operation (baseline), 1 month, 6 month and 12 month after operation |